2022 was a bad year for biotechs in general, money has been...

2022 was a bad year for biotechs in general, money has been pulled from this type of investment, look if it wasnt for the BH global partnership, Orthocell would be trading back in the twenties, but here we are, all waiting for the next lot of announcements too see if our share price will increase and hold increases.

PA should give the market an update, on where these product are, where they are headed and time frames, ACL (ROPE) has blown out again, how on earth do you expect new money to flow into this company when management have no idea when news is delayed time and time again, thats why this company is a small cap. Look eight years Ive owned shares in this company and too this day I shake my head as to why its so hard for management to meet deadline or even get close to. Talk to the investors who have held out for so long, as to why it takes so long for basic result to be on time, surely its not that hard, these guys are running this company like a privately owned company with no one to answer too.